{
    "2018-04-18": [
        [
            {
                "time": "",
                "original_text": "[买入评级]泰格医药(300347)：需求强劲 定价能力增强;上调目标价至人民币62.1元",
                "features": {
                    "keywords": [
                        "泰格医药",
                        "需求强劲",
                        "定价能力",
                        "上调目标价"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "政策支持数字医疗进入高速发展期 六股腾飞良机",
                "features": {
                    "keywords": [
                        "政策支持",
                        "数字医疗",
                        "高速发展",
                        "六股腾飞"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "数字医疗"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}